Aclaris Therapeutics announces Phase 1b proof-of-concept results for ATI-052 in atopic dermatitis and asthma

Aclaris Therapeutics announced Phase 1b proof-of-concept primary analysis results for ATI-052 in atopic dermatitis and asthma, demonstrating rapid, durable skin and itch improvement, improved lung function and reduced airway inflammation.

Detected & updated continuously · Source: Nebula